Chemistry Department, School of Life Sciences, University of Sussex, Brighton BN1 9QJ, U.K. Bio-Techne (Tocris), The Watkins Building, Atlantic Road, Avonmouth ...

Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq ...

Extrachromosomal DNAs (ecDNAs) encode oncogenic driver proteins, regulatory elements, immunomodulators, and genes of yet-unknown oncogenicity (Panel A). They exist as circular pieces of DNA in the ...

"This NDA submission brings us one step closer to our goal of advancing ziftomenib to market as a new therapeutic option for adult patients with R/R NPM1-m AML, a devastating disease for which ...

“This NDA submission brings us one step closer to our goal of advancing ziftomenib to market as a new therapeutic option for adult patients with R/R NPM1-m AML, a devastating disease for which ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the KOMET-001 trial. A new drug application (NDA) seeking the approval of ziftomenib ...

SLS009 significantly improved survival in r/r AML patients, with a median overall survival of 8.8 months, surpassing historical benchmarks. The therapy showed a 67% objective response rate in AML-MRC ...

CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...

In the article by Zhang et al, “Targeting NPM1 Epigenetically Promotes Postinfarction Cardiac Repair by Reprogramming Reparative Macrophage Metabolism,” which published online on February 23, 2024, ...

此外，FLT3、IDH2、NPM1、WT1、CEBPA 和 TP53 等基因的突变是风险分层的因素，特定基因表达模式改变在 AML 诊断和治疗中也至关重要。AML 的关键特征是髓母细胞向成熟髓细胞分化过程受阻，未成熟髓母细胞的存在是疾病诊断标志。 参与髓系造血的 lncRNAs 人类基因组 ...